Great_老虎社区_美港股上老虎

Johnleong
2021-07-17

Great

FDA Says Will Not Object To Distribution Of Chantix With Nitrosamine Below Interim Acceptable Intake Limit<blockquote>FDA表示不会反对亚硝胺含量低于临时可接受摄入量限量的伐尼克兰的分销</blockquote>

July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nit

FDA Says Will Not Object To Distribution Of Chantix With Nitrosamine Below Interim Acceptable Intake Limit<blockquote>FDA表示不会反对亚硝胺含量低于临时可接受摄入量限量的伐尼克兰的分销</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":179385931,"tweetId":"179385931","gmtCreate":1626486763323,"gmtModify":1631891504687,"author":{"id":3581975110248198,"idStr":"3581975110248198","authorId":3581975110248198,"authorIdStr":"3581975110248198","name":"Johnleong","avatar":"https://static.tigerbbs.com/bf6ab9717d202c58a631934c5f8abd6b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great</p></body></html>","htmlText":"<html><head></head><body><p>Great</p></body></html>","text":"Great","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/179385931","repostId":2152068390,"repostType":2,"repost":{"id":"2152068390","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626467099,"share":"https://www.laohu8.com/m/news/2152068390?lang=zh_CN&edition=full","pubTime":"2021-07-17 04:24","market":"hk","language":"en","title":"FDA Says Will Not Object To Distribution Of Chantix With Nitrosamine Below Interim Acceptable Intake Limit<blockquote>FDA表示不会反对亚硝胺含量低于临时可接受摄入量限量的伐尼克兰的分销</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2152068390","media":"T-Reuters","summary":"July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nit","content":"<p><html><body>July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nitrosamine Below The Interim Acceptable Intake Limit.Fda - Will Not Object To Distribution Of Varenicline Tablets With N-Nitroso-Varenicline Below Interim Acceptable Intake Limit Of 185 Ng Per Day.Fda - Continues To Evaluate Data And May Update The Interim Acceptable Limit Of Nitrosamine In Varenicline Tablets In The Future.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</p><p><blockquote><html><body>路透7月16日-美国Fda：：Fda不会反对分销亚硝胺含量低于临时可接受摄入量限值的伐尼克兰（伐尼克兰）。Fda-不会反对分销含有低于临时可接受摄入量限值的N-亚硝基伐尼克兰的伐尼克兰片剂每天185 ng.FDA-继续评估数据，并可能在未来更新伐尼克兰片剂中亚硝胺的临时可接受限量。进一步的公司报道：Pfe.N。（（Reuters.Briefs@Thomsonreuters.Com；））。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Says Will Not Object To Distribution Of Chantix With Nitrosamine Below Interim Acceptable Intake Limit<blockquote>FDA表示不会反对亚硝胺含量低于临时可接受摄入量限量的伐尼克兰的分销</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Says Will Not Object To Distribution Of Chantix With Nitrosamine Below Interim Acceptable Intake Limit<blockquote>FDA表示不会反对亚硝胺含量低于临时可接受摄入量限量的伐尼克兰的分销</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-07-17 04:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nitrosamine Below The Interim Acceptable Intake Limit.Fda - Will Not Object To Distribution Of Varenicline Tablets With N-Nitroso-Varenicline Below Interim Acceptable Intake Limit Of 185 Ng Per Day.Fda - Continues To Evaluate Data And May Update The Interim Acceptable Limit Of Nitrosamine In Varenicline Tablets In The Future.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com;)).</p><p><blockquote><html><body>路透7月16日-美国Fda：：Fda不会反对分销亚硝胺含量低于临时可接受摄入量限值的伐尼克兰（伐尼克兰）。Fda-不会反对分销含有低于临时可接受摄入量限值的N-亚硝基伐尼克兰的伐尼克兰片剂每天185 ng.FDA-继续评估数据，并可能在未来更新伐尼克兰片剂中亚硝胺的临时可接受限量。进一步的公司报道：Pfe.N。（（Reuters.Briefs@Thomsonreuters.Com；））。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152068390","content_text":"July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nitrosamine Below The Interim Acceptable Intake Limit.Fda - Will Not Object To Distribution Of Varenicline Tablets With N-Nitroso-Varenicline Below Interim Acceptable Intake Limit Of 185 Ng Per Day.Fda - Continues To Evaluate Data And May Update The Interim Acceptable Limit Of Nitrosamine In Varenicline Tablets In The Future.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1486,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}